SCHEDULE 13G/A: EcoR1 Capital Increases Passive Stake in iTeos Therapeutics to 14.9%
Beneficial Ownership Disclosure
EcoR1 Capital, LLC and its affiliates have reported an increased passive beneficial ownership of 14.9% in iTeos Therapeutics, Inc., holding 5,730,000 shares of common stock.
Summary
- EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in iTeos Therapeutics, Inc.
- As of May 13, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 5,730,000 shares of iTeos Therapeutics Common Stock, representing 14.9% of the class.
- EcoR1 Capital Fund Qualified, L.P. beneficially owns 5,371,661 shares, representing 14.0% of the class.
- The percentage ownership is calculated based on 38,273,795 shares of Common Stock outstanding as of April 22, 2025, as reported in the Issuer's Form 10-Q for the quarter ended March 31, 2025.
- The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a neutral, factual disclosure of beneficial ownership. The maintenance of a significant stake by a specialized investment firm could be interpreted as a positive signal of confidence in the company's long-term prospects, hence slightly above neutral.
Positives
- A significant institutional investor, EcoR1 Capital, maintaining or increasing a large passive stake (14.9%) in iTeos Therapeutics can be interpreted as a positive signal of confidence in the company's long-term prospects and strategy.
Future Outlook
No specific future outlook or guidance is provided in this beneficial ownership disclosure.
Management Comments
- Oleg Nodelman, on behalf of the reporting persons, certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
iTeos Therapeutics operates in the biotechnology sector, focusing on novel immunotherapies. EcoR1 Capital is a healthcare-focused investment firm, indicating continued specialized investment interest in the biotech industry, particularly in companies like iTeos Therapeutics.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a specialized investor in the company's future.
Key Dates
| Date | Description |
|---|---|
| April 22, 2025 | Date on which 38,273,795 shares of Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| May 13, 2025 | Date of event requiring the filing of this statement and the filing date of the Schedule 13G Amendment No. 1. |
Keywords
iTeos Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.